^
CANCER:

Gastrointestinal Cancer

FGFR2 rearrangement
Cholangiocarcinoma
pemigatinib
Sensitive: A1 - Approval
Innovent Biologics Press Release - 3 days
FGFR2 fusion
Cholangiocarcinoma
pemigatinib
Sensitive: A1 - Approval
Innovent Biologics Press Release - 3 days
PD-L1 expression
Gastric Cancer
tislelizumab
Sensitive: B - Late Trials
BeiGene Press Release - 4 days
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
tislelizumab
Sensitive: B - Late Trials
BeiGene Press Release - 4 days
PD-L1 overexpression
Gastric Cancer
pembrolizumab
Sensitive: B - Late Trials
ASCO-GI 2022 - 1 week
PD-L1 overexpression
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: B - Late Trials
ASCO-GI 2022 - 1 week
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
CYNK-101
Sensitive: B - Late Trials
Celularity Press Release - 1 week
HER-2 positive
Gastric Cancer
CYNK-101
Sensitive: B - Late Trials
Celularity Press Release - 1 week
GPX4 rs4807542
CRC
cetuximab
Sensitive: B - Late Trials
ASCO-GI 2022 - 1 week
TXN2 rs4821494
CRC
cetuximab
Sensitive: B - Late Trials
ASCO-GI 2022 - 1 week
PD-L1 overexpression
Esophageal Adenocarcinoma
nivolumab
Sensitive: B - Late Trials
ASCO-GI 2022 - 1 week
PD-L1 overexpression
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: B - Late Trials
ASCO-GI 2022 - 1 week
PD-L1 overexpression
Gastric Cancer
nivolumab
Sensitive: B - Late Trials
ASCO-GI 2022 - 1 week
HER-2 positive
Gastric Cancer
nivolumab + trastuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
PD-L1 expression
Rectal Cancer
nivolumab
Sensitive: C3 – Early Trials
Clin Cancer Res - 1 week
FGFR1 fusion
Cholangiocarcinoma
erdafitinib
Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
PD-L1 overexpression + TMB-H
Anal Carcinoma
EGFR inhibitor + Immunotherapy
Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
KRAS mutation
CRC
bevacizumab + PCM-075
Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
KRAS mutation
CRC
pembrolizumab + selinexor
Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab + ramucirumab
Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
MSI-H/dMMR
Gastrointestinal Cancer
Immunotherapy
Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
DKK1 overexpression
Gastroesophageal Junction Adenocarcinoma
tislelizumab + DKN-01
Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
HRAS mutation
CRC
pembrolizumab + selinexor
Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
NRAS mutation
CRC
pembrolizumab + selinexor
Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
GAST expression
Gastric Cancer
PAS
Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
CCKBR expression
Gastric Cancer
PAS
Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
PD-L1 expression
Gastric Cancer
PAS
Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
HLA-A*02
Gastric Cancer
GSK2636771
Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
PIK3R1 M326I
Gastric Cancer
GSK2636771
Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
RAS wild-type
CRC
EGFR inhibitor
Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
MSI-H/dMMR
Gastroesophageal Junction Adenocarcinoma
tislelizumab
Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
ATM mutation
Gastrointestinal Cancer
rucaparib
Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
TMB-L
CRC
bevacizumab
Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab + camrelizumab
Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
HER-2 positive
Gastric Cancer
trastuzumab + camrelizumab
Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
KRAS G12C
Pancreatic Ductal Adenocarcinoma
MRTX849
Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
TNFRSF9 elevation
HCC
sintilimab + Byvasda (bevacizumab biosimilar)
Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trifluridine/tipiracil
Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
HER-2 positive
Gastric Cancer
trifluridine/tipiracil
Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
HER-2 positive
Gastric Cancer
nivolumab + trastuzumab + gimeracil/oteracil/tegafur
Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
KRAS wild-type
Pancreatic Ductal Adenocarcinoma
gemcitabine + albumin-bound paclitaxel
Sensitive: C3 – Early Trials
Cancer - 1 week
GOPC-ROS1 fusion + KRAS Q61H
CRC
crizotinib
Resistant: C4 – Case Studies
ASCO-GI 2022 - 1 week
FGFR2 mutation
Gastric Cancer
KIN-3248
Sensitive: D – Preclinical
ASCO-GI 2022 - 1 week
FGFR2 mutation
Cholangiocarcinoma
KIN-3248
Sensitive: D – Preclinical
ASCO-GI 2022 - 1 week
KRAS mutation
Pancreatic Ductal Adenocarcinoma
RMC-6236
Sensitive: D – Preclinical
ASCO-GI 2022 - 1 week
MYC overexpression
Gastric Cancer
WB100
Sensitive: D – Preclinical
Adv Sci (Weinh) - 1 week
MYC overexpression
Pancreatic Ductal Adenocarcinoma
WB100
Sensitive: D – Preclinical
Adv Sci (Weinh) - 1 week
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
ramucirumab
Sensitive: B - Late Trials
Gastric Cancer - 2 weeks
HER-2 positive
Gastric Cancer
ramucirumab
Sensitive: B - Late Trials
Gastric Cancer - 2 weeks
HIF1A overexpression
CRC
5-fluorouracil
Resistant: D – Preclinical
J Exp Clin Cancer Res - 2 weeks
HRAS mutation
CRC
bevacizumab
Resistant: C3 – Early Trials
Br J Cancer - 3 weeks
CDH1 deletion
Gastric Cancer
vorinostat
Sensitive: D – Preclinical
Cancers (Basel) - 4 weeks
CDH1 deletion
Gastric Cancer
MGCD0103
Sensitive: D – Preclinical
Cancers (Basel) - 4 weeks
CDH1 deletion
Gastric Cancer
SB939
Sensitive: D – Preclinical
Cancers (Basel) - 4 weeks
CDH1 deletion
Gastric Cancer
SNDX-275
Sensitive: D – Preclinical
Cancers (Basel) - 4 weeks
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
No biomarker
Esophageal Cancer
nivolumab
Sensitive: A1 - Approval
No biomarker
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: A1 - Approval
No biomarker
Esophageal Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
No biomarker
Gastric Cancer
nivolumab
Sensitive: A1 - Approval
No biomarker
Gastric Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A1 - Approval
HER-2 positive
Gastric Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
ASCO-GI 2022 - 1 week
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
ASCO-GI 2022 - 1 week
BRCA2 mutation
Pancreatic Cancer
olaparib
Sensitive: A1 - Approval
No biomarker
HCC
pembrolizumab
Sensitive: A1 - Approval
Merck (MSD) Press Release - 1 week
No biomarker
HCC
bevacizumab + atezolizumab
Sensitive: A1 - Approval
BRCA1 mutation
Pancreatic Cancer
olaparib
Sensitive: A1 - Approval
FGFR2 rearrangement
Cholangiocarcinoma
infigratinib
Sensitive: A1 - Approval
FGFR2 fusion
Cholangiocarcinoma
infigratinib
Sensitive: A1 - Approval
IDH1 mutation
Cholangiocarcinoma
ivosidenib
Sensitive: A1 - Approval
MSI-H/dMMR
CRC
pembrolizumab
Sensitive: A1 - Approval
MSI-H/dMMR
CRC
nivolumab + ipilimumab
Sensitive: A1 - Approval
ASCO-GI 2022 - 1 week
No biomarker
Gastric Cancer
TPF
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
TPF
Sensitive: A1 - Approval
HER-2 positive
Gastric Cancer
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
BRAF V600E
CRC
cetuximab + binimetinib + encorafenib
Sensitive: A1 - Approval
ASCO-GI 2022 - 1 week
BRAF V600E
CRC
cetuximab + encorafenib
Sensitive: A1 - Approval
ASCO-GI 2022 - 1 week
No biomarker
Colon Cancer
capecitabine
Sensitive: A1 - Approval
No biomarker
Rectal Cancer
FOLFIRI
Sensitive: A1 - Approval
No biomarker
Colon Cancer
5-fluorouracil + irinotecan
Sensitive: A1 - Approval
PD-L1 expression
Esophageal Squamous Cell Carcinoma
pembrolizumab
Sensitive: A1 - Approval
No biomarker
CRC
bevacizumab
Sensitive: A1 - Approval
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A1 - Approval
HER-2 negative + PD-L1 expression
Gastric Cancer
nivolumab
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
trastuzumab
Sensitive: A1 - Approval
No biomarker
Esophageal Cancer
pembrolizumab
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Rectal Cancer
Mvasi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Colon Cancer
Mvasi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Colon Cancer
Zirabev (bevacizumab biosimilar)
Resistant: A1 - Approval
No biomarker
CRC
trifluridine/tipiracil
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
trifluridine/tipiracil
Sensitive: A1 - Approval
Gastric Cancer - 2 weeks
No biomarker
Gastric Cancer
trifluridine/tipiracil
Sensitive: A1 - Approval
Gastric Cancer - 2 weeks
No biomarker
Pancreatic Adenocarcinoma
gemcitabine + albumin-bound paclitaxel
Sensitive: A1 - Approval
No biomarker
Pancreatic Adenocarcinoma
5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan
Sensitive: A1 - Approval
No biomarker
Gastric Cancer
ramucirumab
Sensitive: A1 - Approval
No biomarker
HCC
cabozantinib tablet
Sensitive: A1 - Approval
No biomarker
CRC
ziv-aflibercept IV
Sensitive: A1 - Approval
No biomarker
Gastric Cancer
capecitabine
Sensitive: A1 - Approval
No biomarker
CRC
capecitabine
Sensitive: A1 - Approval
No biomarker
Pancreatic Cancer
erlotinib
Sensitive: A1 - Approval
EGFR expression
CRC
cetuximab
Sensitive: A1 - Approval
KRAS Q61
CRC
cetuximab
Resistant: A1 - Approval
No biomarker
CRC
ramucirumab
Sensitive: A1 - Approval
KRAS A146
CRC
cetuximab
Resistant: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
ramucirumab
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Rectal Cancer
irinotecan
Sensitive: A1 - Approval
No biomarker
Colon Cancer
irinotecan
Sensitive: A1 - Approval
No biomarker
HCC
sintilimab + Byvasda (bevacizumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
PD-L1 expression
Esophageal Cancer
pembrolizumab
Sensitive: A1 - Approval
AFP elevation
HCC
ramucirumab
Sensitive: A1 - Approval
No biomarker
HCC
regorafenib
Sensitive: A1 - Approval
No biomarker
HCC
lenvatinib
Sensitive: A1 - Approval
No biomarker
HCC
sorafenib
Sensitive: A1 - Approval
KRAS G13
CRC
cetuximab
Resistant: A1 - Approval
KRAS G12
CRC
cetuximab
Resistant: A1 - Approval
No biomarker
CRC
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
MSI-H/dMMR
CRC
nivolumab
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
No biomarker
CRC
regorafenib
Sensitive: A1 - Approval
KRAS K117
CRC
cetuximab
Resistant: A1 - Approval
KRAS A59
CRC
cetuximab
Resistant: A1 - Approval
No biomarker
HCC
nivolumab + ipilimumab
Sensitive: A1 - Approval
HER-2 positive
Gastric Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
KRAS G12S
CRC
panitumumab
Resistant: A1 - Approval
NRAS Q61
CRC
cetuximab
Resistant: A1 - Approval
NRAS Q61
CRC
panitumumab
Resistant: A1 - Approval
NRAS G13
CRC
panitumumab
Resistant: A1 - Approval
NRAS G13
CRC
cetuximab
Resistant: A1 - Approval
NRAS G12
CRC
panitumumab
Resistant: A1 - Approval
NRAS G12
CRC
cetuximab
Resistant: A1 - Approval
NRAS A146
CRC
cetuximab
Resistant: A1 - Approval